MaxCyte is a leader in cell transfection, bringing to market its patented flow electroporation technology. MaxCyte is focused in applying its significant capabilities in the discovery, development, and manufacturing of virtually all classes of innovative therapeutics targeting a broad range of chronic and acute diseases. MaxCyte’s customers and partners utilize its technologies in the development and commercialization of cell-based therapies in regenerative medicineand active cell immunotherapies and in the discovery and development of protein drugs, monoclonal antibodies, vaccines, and small molecule drugs. This clinical-grade cell loading technology is fully developed and well validated and has received Master File designation with the CBER Division of the U.S. FDA, has been cleared by NIH’s RAC and Health Canada, and is commercialized in Japan. Considerable energy is devoted to R&D on new applications. These efforts have lead to the expanded application of our technology in pharmaceutical and biotherapeutic drug discovery pipelines. Our instrumentation is currently placed in most of the major global pharmaceutical companies and is used for high throughput/high content screening and preclinical protein production. MaxCyte’s technology uniquely fulfills the needs for high quality, fully scalable cell modification in both the clinical and R&D arenas.

MaxCyte’s technology is protected by U.S. patents issued and allowed, with over 40 U.S. and international pending patents.

See all Members